These innovative compounds represent a significant progression in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose https://barbaratonv796924.bloginder.com/39810905/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide